Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$0.72
-0.02 (-2.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-1.2M · quality 34.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$28M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-14.4%
↓Gross Margin
16.9%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1.7%
FCF / Net income
0.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $69.3M · net income $-5.3M · FCF $-1.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $69.3M | $69.3M | $101.5M | $83.6M | $72.8M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | $-5.3M | $-5.3M | $-480000.00 | $-8.4M | $-18.7M | $-32.7M | $-30.9M | $-34.1M | $-32.1M | $-25.9M | $-19.8M | $-14.4M | $-21.3M | $-48.8M | $-54.0M | $-21.4M | $-2.7M | $-5.5M |
| EBITDA | $-2.0M | $-2.0M | $3.0M | $-4.7M | $-16.2M | $-29.7M | $-27.6M | $-33.7M | $-31.8M | $-25.4M | $-19.4M | $-14.3M | $-16.6M | $-46.1M | $-53.2M | $-20.5M | $-1.5M | $-4.2M |
| EPS | -0.15 | -0.15 | -0.03 | -0.37 | -1.89 | -3.83 | -4.51 | — | — | -5.61 | -4.29 | -3.19 | -5.72 | — | — | — | — | — |
| Gross Margin | 16.9% | 16.9% | 17.2% | 10.4% | 5.6% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -6.8% | -6.8% | 0.6% | -8.0% | -23.0% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -7.7% | -7.7% | -0.5% | -10.1% | -25.7% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | — | — | — | — | — | 5.20 | 0.61 | 0.00 | — | — | — | — | — | 30.09 | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-1.2M | $-1.2M | $3.2M | $-9.7M | $-17.2M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | -14.4% | -14.4% | -1.5% | -39.6% | -132.4% | -1288.9% | -90.4% | -168.0% | -117.8% | -78.8% | -37.4% | -23.1% | -31.0% | -8191.5% | 542.3% | -117.5% | -8.8% | -18.8% |
| Valuation | ||||||||||||||||||
| EV/EBITDA | — | — | 19.20 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.70 | 0.70 | 2.22 | 1.92 | 0.80 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -31.8% | -31.8% | 21.4% | 14.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | -400.0% | -400.0% | 91.9% | 80.4% | — | 15.1% | — | — | — | -30.8% | -34.5% | 44.2% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.15
Residual
-26.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.